Liquidia settles all litigation with United Therapeutics for $380.7M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Liquidia settles all litigation with United Therapeutics for $380.7M

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

October 13, 2026 5:44 PM EDT

Fully resolves all six ongoing lawsuits between the companiesMaintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH)Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United TherapeuticsStrong financial position with $222.7 million in Q326 YUTREPIA net product sales (preliminary, unaudited), contributing to $396.1 million in cash and cash equivalents as of September 30, 2026Liquidia will continue to advance YUTREPIA and L606 clinical programs as previously... More